As I have mentioned in prior postings, one of my tasks this year as AIPLA President is to represent U.S. intellectual property interests around the world. (By the way, I learned that people in some South American countries pronounce our country’s U.S.A. initials as a word, such as asking “Are you from Ooh-SAh?”) There are a number of issues that keep coming up in discussion, but the one I’d like to focus on today is “patent attorneys” and privilege.
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
In the first of a two-part article, lawyers at Spruson & Ferguson and Marshall Gerstein provide an overview of China’s system for appealing against patent invalidation decisions
Lawyers and corporate leaders at INTA’s Business of M&A conference in New York discussed how cross-practice collaboration and early in-house involvement can help deals
Top talking points also included news of an appellate ruling concerning ‘Pisco’ and Indian drugmakers gearing up to launch generic versions of Ozempic as Novo Nordisk’s patent expires
The government’s keenly awaited view on AI and copyright has positive themes but leaves rights owners wanting, says Rebecca Newman at Addleshaw Goddard
While IP Australia’s updated manual could be favourable to computer-implemented inventions, stakeholders would like to see whether a consistent and reliable standard is followed during actual examination
US patent lawyers say they are increasingly advising clients on China strategies as corporations seek to gain leverage in enforcement, licensing, and supply chain management